A generic alternative indicated for Diabetes. Administration promotes renal glucose excretion to assist in the long-term management of blood sugar levels.
Indicated to address high blood sugar and target cardiovascular risks to alleviate metabolic strain and support kidney health in type 2 diabetes patients.
Mechanism of Action
Canagliflozin blocks the SGLT2 protein in the kidneys, which normally reabsorbs sugar back into the blood. By inhibiting this protein, the body excretes excess glucose through the urine, effectively lowering blood sugar levels.
Route of Administration
Oral
Onset Time
1–2 hours
Duration
24 hours
Contraindications
Severe renal impairment, Dialysis, Type 1 diabetes, Diabetic ketoacidosis
Information for Invokana is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.